galectin therapeutics inc (GALT) Snapshot

To update on the company's pipeline of galectin inhibitor compounds and progress in its development of treatments for liver fibrosis and cancer

Galectin Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total operating loss of $3,208,000 against $1,953,000 a year ago. Net loss was $3,203,000 against $1,950,000 a year ago. Net loss applicable to common stock was $3,472,000 against $2,204,000 a year ago. Basic and diluted net loss per share was $0.22 against $0.17 a year ago.

Galectin Therapeutics, Inc., Annual General Meeting, May 23, 2013., at 09:00 US Eastern Standard Time. Location: The offices of Arnall Golden Gregory LLP171 17th Street NW, Suite 2100. Agenda: To elect the eight nominees named in this proxy statement for director to hold office for a one-year term, expiring at the 2014 annual meeting of stockholders; to vote on a non-binding advisory resolution to approve the compensation paid to Galectin’s named executive officers; to recommend, by non-binding vote, the frequency with which Galectin will conduct stockholder advisory votes on executive compensation; to ratify the selection by the Audit Committee of the Board of Directors of McGladrey LLP as independent registered public accounting firm for the fiscal year ending December 31, 2013; and to conduct any other business properly brought before the meeting.